Repertoire Immune Medicines Doses First Patient in RPTR-1-201 Phase 1/2 Trial for Advanced Solid Tumors

Key Takeaways

• First patient dosed in Phase 1/2 clinical trial of RPTR-1-201, a TCR bispecific therapy for advanced solid tumors
• Trial represents major milestone for Repertoire’s programmable T cell-targeted immune medicine platform
• Multi-site study launching across United States and Europe following regulatory clearance

---

Cambridge, Mass. - April 23, 2026 - Repertoire Immune Medicines has achieved a significant clinical milestone by dosing the first participant in its Phase 1/2 trial of RPTR-1-201, marking the biotechnology company’s entry into human testing for its novel T cell-targeted immune medicine approach.

Revolutionary TCR Bispecific Therapy

RPTR-1-201 represents a new class of TCR (T-cell receptor) bispecific therapies specifically engineered to treat advanced solid tumors. The investigational drug leverages Repertoire’s proprietary platform for discovering and developing programmable T cell-targeted immune medicines, potentially offering patients with limited treatment options a new therapeutic avenue.

Global Clinical Trial Launch

The Phase 1/2 study is being conducted across multiple clinical sites in both the United States and Europe, following successful clearance of Repertoire’s Investigational New Drug (IND) application. This international approach allows the company to accelerate patient enrollment while gathering diverse clinical data across different populations.

Market Impact and Innovation

The initiation of this trial positions Repertoire Immune Medicines as a notable player in the competitive oncology immunotherapy space. TCR bispecific therapies represent an emerging treatment modality that aims to redirect patients’ own T cells to recognize and eliminate cancer cells more effectively than traditional approaches.

For patients with advanced solid tumors who have exhausted standard treatment options, RPTR-1-201 could potentially offer new hope. The therapy’s programmable design allows for precise targeting of tumor-associated antigens while minimizing damage to healthy tissue.

Next Steps and Timeline

The Phase 1/2 trial will primarily focus on establishing the safety profile and determining the optimal dosing of RPTR-1-201, while also collecting preliminary efficacy data. Results from this study will inform the design of potential future Phase 3 trials and regulatory submissions.

---

Frequently Asked Questions

What does this mean for patients with advanced solid tumors?

This trial offers potential access to a novel TCR bispecific therapy for patients who may have limited treatment options, though the therapy is still experimental and undergoing safety testing.

When will RPTR-1-201 be available as a treatment?

The drug is currently in early-stage Phase 1/2 trials. If successful, it would need to complete additional Phase 3 studies and regulatory approval, which typically takes several years.

How does RPTR-1-201 differ from existing cancer treatments?

RPTR-1-201 is a TCR bispecific therapy that programs patients’ T cells to better recognize and attack cancer cells, representing a newer approach compared to traditional chemotherapy or radiation.